Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeremiah Bushmaker

Podiatrist, Foot Surgery Galesburg, IL Doctor of Podiatric Medicine

NPI 1114133014 CMS profile 322846

3315 N Seminary St, Galesburg, IL 61401

Open in the dashboard

General payments

$4,907

178 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeremiah Bushmaker of Galesburg, IL is reported in the CMS Open Payments database as having received $4,907 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Podiatrist, Foot Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $411 12
2024 General $1,102 25
2023 General $271 9
2022 General $929 23
2021 General $512 20
2020 General $513 29
2019 General $1,169 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeremiah Bushmaker
  • Podiatrist, Foot Surgery median
  • Middle half of Podiatrist, Foot Surgery
  • National median

In program year 2025, general payments to Jeremiah Bushmaker were reported at $411. Among 732 Podiatrist, Foot Surgery profiles paid that year, the median was $180 and the middle half received between $70 and $569.

Show as a table
Year Jeremiah Bushmaker Podiatrist, Foot Surgery median Middle half National median
2019 $1,169 $167 $67–$484 $163
2020 $513 $114 $40–$323 $114
2021 $512 $171 $57–$502 $132
2022 $929 $196 $66–$556 $149
2023 $271 $187 $78–$466 $160
2024 $1,102 $190 $78–$557 $164
2025 $411 $180 $70–$569 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $3,073 134 payments
  2. Stryker Corporation $1,083 17 payments
  3. Osiris Therapeutics Inc. $432 19 payments
  4. Integra LifeSciences Corporation $112 2 payments
  5. Janssen Pharmaceuticals, Inc $90 1 payment
  6. Organogenesis Inc. $53 1 payment
  7. Solventum Corporation $17 1 payment
  8. Wardlow Enterprises $17 1 payment
  9. KCI USA, Inc $17 1 payment
  10. Tactile Systems Technology Inc $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,579 177 payments
  2. Travel and Lodging $328 1 payment
Products named General payments · program years 2019–2025
  1. GRAFIX PL Other Advanced Wound Management $1,226 40 payments
  2. GRAFIX Other Advanced Wound Management $1,036 49 payments
  3. STRAVIX Extremities & Limb Restoration $931 30 payments
  4. Stravix Other Advanced Wound Management $917 47 payments
  5. GrafixPL $681 32 payments
  6. ORTHOLOC 3DI $557 8 payments
  7. GRAFIX PL Other Advanced Wound Management $514 23 payments
  8. STRAVIX PL Extra Cellular Matrix $355 8 payments
  9. GRAFIX Other Advanced Wound Management $245 5 payments
  10. STRAVIX PL Extra Cellular Matrix $220 7 payments
  11. Other $1,882 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

470

Median for Podiatry: 160

Drug cost

$6,301

Median for Podiatry: $2,368

Branded share of claims

24%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ammonium Lactate Generic 137 $2,917
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 80 $799
Neomycin-Polymyxin-Hydrocort Neomycin/Polymyxin B/Hydrocort Brand 12 $585
Cephalexin Generic 51 $419
Mupirocin Generic 32 $387
Diclofenac Sodium Generic 32 $330
Doxycycline Hyclate Generic 17 $259
Clindamycin Hcl Generic 23 $185
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 21 $183
Prednisone Generic 23 $103

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$73,176

Medicare's payments for the services billed

Medicare patients

423

Average age 73

Services billed

1,246

225 women, 198 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 44%
Chronic kidney disease 36%
COPD 26%
Ischemic heart disease 25%
Heart failure 24%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record